carnitine has been researched along with Diabetic Nephropathies in 11 studies
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We orally administered L-carnitine, which exerts protective effects on the mitochondria, to obesity-induced DN (db/db) mice for 8 weeks." | 4.12 | Effects of L-Carnitine Treatment on Kidney Mitochondria and Macrophages in Mice with Diabetic Nephropathy. ( Imakiire, T; Ishikiriyama, T; Ito, S; Kinoshita, M; Kumagai, H; Nakashima, H; Nakashima, M; Oshima, N; Seki, S; Yamagata, A, 2022) |
| "The pathogenesis of diabetic kidney disease is complex, and fundamental research is still required to provide a better understanding of the driving forces behind it." | 1.51 | Metabolite aberrations in early diabetes detected in rat kidney using mass spectrometry imaging. ( Bergman, HM; Kihlberg, J; Lanekoff, I; Lindfors, L; Palm, F, 2019) |
| "Hyperlipidemia is a risk factor for initiation and progression of diabetic nephropathy but the metabolic pathways altered in the diabetic kidney in a context of hyperlipidemia remain incompletely described." | 1.46 | Increased urine acylcarnitines in diabetic ApoE-/- mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia. ( Bascands, JL; Denis, C; Gillet, M; Klavins, K; Klein, J; Koal, T; Marsal, D; Mirzoyan, K; Saulnier-Blache, JS; Schanstra, JP, 2017) |
| "l-Carnitine treatment also prevented decreased mRNA expressions of nephrin and podocin in the high glucose-stimulated podocytes." | 1.36 | Ameliorating effects of L-carnitine on diabetic podocyte injury. ( Fan, JP; Ha, TS; Han, GD; Kawachi, H; Kim, D, 2010) |
| " Drug-treated animals had significant lowering of fasting glucose at 0 and 4 h after dosing during the midportion of the study (2-6 wk)." | 1.26 | Metabolic control of prevention of nephropathy by 2-tetradecylglycidate in the diabetic mouse (db/db). ( Bressler, R; Kircher, CH; Lee, SM; Tutwiler, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S | 1 |
| Nakashima, M | 1 |
| Ishikiriyama, T | 1 |
| Nakashima, H | 1 |
| Yamagata, A | 1 |
| Imakiire, T | 1 |
| Kinoshita, M | 1 |
| Seki, S | 1 |
| Kumagai, H | 1 |
| Oshima, N | 1 |
| Mirzoyan, K | 1 |
| Klavins, K | 1 |
| Koal, T | 1 |
| Gillet, M | 1 |
| Marsal, D | 1 |
| Denis, C | 1 |
| Klein, J | 1 |
| Bascands, JL | 1 |
| Schanstra, JP | 1 |
| Saulnier-Blache, JS | 1 |
| Bergman, HM | 1 |
| Lindfors, L | 1 |
| Palm, F | 1 |
| Kihlberg, J | 1 |
| Lanekoff, I | 1 |
| Fan, JP | 1 |
| Kim, D | 1 |
| Kawachi, H | 1 |
| Ha, TS | 1 |
| Han, GD | 1 |
| Takenaka, T | 1 |
| Kanno, Y | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 1 |
| Lee, SM | 1 |
| Tutwiler, G | 1 |
| Bressler, R | 1 |
| Kircher, CH | 1 |
| Bartel, LL | 1 |
| Hussey, JL | 1 |
| Shrago, E | 1 |
| Gumprecht, J | 1 |
| Snit, M | 1 |
| Zukowska-Szczechowska, E | 1 |
| Grzeszczak, W | 1 |
| Moczulski, D | 1 |
| Jendryczko, A | 1 |
| Reddi, AS | 1 |
| Moquete, M | 1 |
| Keshav, G | 1 |
| DeAngelis, B | 1 |
| Frank, O | 1 |
| Baker, H | 1 |
| Dellow, WJ | 1 |
| Chambers, ST | 1 |
| Lever, M | 1 |
| Lunt, H | 1 |
| Robson, RA | 1 |
| Matsumura, M | 1 |
| Nakashima, A | 1 |
| Araki, T | 1 |
| Tofuku, Y | 1 |
| Koizumi, J | 1 |
| Yagi, K | 1 |
| Koni, I | 1 |
| Mabuchi, H | 1 |
11 other studies available for carnitine and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of L-Carnitine Treatment on Kidney Mitochondria and Macrophages in Mice with Diabetic Nephropathy.
Topics: Animals; Carnitine; Diabetes Mellitus; Diabetic Nephropathies; DNA, Mitochondrial; Kidney; Macrophag | 2022 |
Increased urine acylcarnitines in diabetic ApoE-/- mice: Hydroxytetradecadienoylcarnitine (C14:2-OH) reflects diabetic nephropathy in a context of hyperlipidemia.
Topics: Animals; Apolipoproteins E; Biomarkers; Carnitine; Diabetic Nephropathies; Hyperlipidemias; Male; Mi | 2017 |
Metabolite aberrations in early diabetes detected in rat kidney using mass spectrometry imaging.
Topics: Amino Acids, Branched-Chain; Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetic Nephropat | 2019 |
Ameliorating effects of L-carnitine on diabetic podocyte injury.
Topics: Animals; Carnitine; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Express | 2010 |
Key role of insulin resistance in vascular injury among hemodialysis patients.
Topics: Aged; Blood Pressure; Carnitine; Cyclohexanes; Diabetic Nephropathies; Female; Homeostasis; Humans; | 2007 |
Metabolic control of prevention of nephropathy by 2-tetradecylglycidate in the diabetic mouse (db/db).
Topics: Animals; Blood Glucose; Carnitine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epoxy Co | 1982 |
Effect of dialysis on serum carnitine, free fatty acids, and triglyceride levels in man and the rat.
Topics: Animals; Carnitine; Diabetic Nephropathies; Fatty Acids, Nonesterified; Humans; Kidney Failure, Chro | 1982 |
[Level of total plasma carnitine in patients with chronic renal failure in the course of diabetes and other etiologies treated with hemodialysis].
Topics: Adult; Carnitine; Cellulose; Diabetic Nephropathies; Female; Humans; Kidney Failure, Chronic; Male; | 1995 |
Plasma carnitine levels in patients undergoing hemodialysis.
Topics: Adult; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kid | 1998 |
Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Betaine; Biomarkers; Carnitine; Creatinine; Diabetes Mell | 1999 |
L-Carnitine supplementation in a hemodialysis patient with a mutation in the mitochondrial tRNA(Leu(UUR)) gene.
Topics: Adult; Carnitine; Diabetic Nephropathies; DNA, Mitochondrial; DNA, Ribosomal; Heart; Humans; Kidney | 2000 |